Introduction
ATO is a clinically approved cancer therapeutic drug that is effective in treatment of APL both as a single agent as well as in combination with all-trans retinoic acid (ATRA) [1] [2] [3] [4] [5] .
This is a targeted therapy as recent studies have demonstrated direct interactions between
ATO and the PML moiety of the PML/RARA oncoprotein, the product of the APL-specific t(15;17) chromosomal translocation 6, 7 . At the molecular level this drug causes PML and PML/RARA SUMOylation and Ubiquitination, biochemical modifications that promote degradation of these proteins by the proteasome [8] [9] [10] . In addition, ATO has been shown to stimulate lysosome-dependent degradation of PML/RARA through activation of autophagy 11 .
Such therapy-induced degradation of PML/RARA has been proposed to contribute to clinical remission through decreased self-renewal capacity as well as increased differentiation of the malignant APL cells [12] [13] [14] .
The PML protein, expressed from its normal non-rearranged gene in APL or non-APL cells, is a tumor suppressor implicated in multiple cellular activities, including apoptosis, senescence, differentiation and genome maintenance 15 . A characteristic and unique feature of this protein is its ability to induce the formation of cellular compartments called PML bodies.
These structures are readily detected within the nucleus of most mammalian cells by conventional immunofluorescence microscopy as 10 to 20 foci ranging in size from 0.1 to 1.0 µm [15] [16] [17] .
PML bodies are highly dynamic structures that change their morphology, sub-cellular distribution and protein composition in a cell cycle-dependent manner [15] [16] [17] . During interphase they primarily reside within the nucleus, where they dynamically recruit and release a multitude of proteins with diverse cellular functions [15] [16] [17] . Upon entry into mitosis, several PML body resident proteins, including SUMO, Daxx and sp100, dissociate concomitant with increased aggregation of these structures into mitotic bodies referred to as mitotic assemblies of PML proteins (MAPPs) [18] [19] [20] . At the end of mitosis the MAPPs are consistently excluded from the interior of progeny daughter nuclei [19] [20] [21] , and at entry into G1 they complex with
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Several observations suggest that CyPNs represent transient intermediates between
MAPPs and nuclear PML bodies. Firstly, CyPNs gradually disappear during early G1 phase concomitant with repopulation of the nucleus with new PML bodies [18] [19] [20] [21] . Secondly, PML proteins carrying mutations within their nuclear import motif fail to support formation of CyPNs upon expression in the cytoplasm, suggesting that formation of these structures is coupled to nuclear translocation of PML 21 . Lastly, generation of PML bodies during G1 has been shown to occur in the absence of protein synthesis, showing that PML bodies from the previous cell cycle are recycled to the next generation of daughter nuclei in order to participate in construction of progeny PML bodies 19 .
In the present study we show that ATO causes CyPN stabilization concomitant with inhibition of nuclear PML body formation following progression of cells through mitosis,
suggesting that this drug blocks the cell cycle-dependent PML body circuit at the level of nuclear import. Notably, both PML and PML/RARA are recruited to CyPNs, and in contrast to ATO-induced protein degradation, stimulation of CyPN accumulation does not require PML SUMOylation. Finally, stabilization of CyPNs is primarily activated by relatively low ATO concentrations ranging from 0.01 to 1.0 µM, and PML and PML/RARA carrying mutations associated with resistance to ATO-based therapy were found to have reduced affinity for these cytoplasmic compartments. Thus, post mitotic accumulation of CyPNs may represent a mechanism that operates in parallel with degradation to restrict nuclear activities of PML and PML/RARA in the presence of ATO.
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Materials and methods

Immunofluorescence and analysis of CyPNs
Adherent cells (HaCaT and HEF cells) were grown on coverslips and fixed in 4 % paraformaldehyde (PFA) in PBS. Cells grown in suspension (NB4, T2 and Human CD34+ cells) were subjected to Cytospin centrifugation and air dried for 60 minutes prior to fixation in 4 % PFA in PBS. After permeabilization with 0.3 % Triton X-100, fixed cells were processed for immunofluorescence (IF) as previously described 22 . The following antibodies were used: Rabbit anti-PML (H-238; Santa Cruz Biotechnology), mouse anti-PML (PG-M3; Santa Cruz Biotechnology), nucleoporin specific mouse Mab414 antibody (Abcam), mouse anti-Nup153 (Abcam), mouse anti-SUMO-1 (GMP-1; Invitrogen), mouse anti-FLAG (Sigma) and rabbit anti-RARA (C-20; Santa Cruz Biotechnology).
For quantification of CyPNs we acquired confocal microscopy images using the LSM 110 confocal microscopy system equipped with a 40x lens on an Axiovert Observer Z1 microscope. For each sample 6 to 10 different fields of view were selected randomly, and images were generated by projection of 6 to 10 Z-scans that spanned the entire cell. Each cell in an image was manually inspected, and CyPNs were scored if PML and nucleoporins accumulated and colocalized within distinct foci. The same criteria were used for scoring of RARA/nucleoporin-positive foci, except that anti-RARA, instead of anti-PML, was used.
Lentivirus production and preparation of cell lines with stable transgene expression
Lentivirus-based vectors expressing shRNAs against PML and Luciferase has been described previously 23 . The lentivirus vector pLKOneo-FLAG-PML.I, which expresses FLAG-tagged PML1 from a CMV promoter, was also generously provided by Dr Everett. The patient mutations were introduced into pLNGY-PML.I using the QuickChange mutagenesis kit (Stratagene). To obtain lentivirus vectors expressing wild type and mutated PML/RARA, cDNAs containing these transgenes were placed into pLenti-PGK-Neo-DEST (Addgene) using Gateway cloning technology (Invitrogen).
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To produce lentivirus particles, 293T cells were co-transfected with one of the lentivirus constructs and the helper plasmids pVSV-G and pCMV-DR8.91 at a 2 Figure 1A and B). Maximal stimulation was observed between 0.1 and 1.0 µM ( Figure 1C and D), a concentration range that roughly equals that observed in serum of APL patients receiving ATO-based therapy [26] [27] [28] . Concomitant with increased levels of cytoplasmic PML, we noted a decrease in the number and intensity of nuclear PML bodies ( Figure 1A and B).
ATO has previously been shown to cause oxidative stress in NB4 cells leading to arrest in mitosis at 1.0 µM or higher concentrations 29 . Accordingly, quantitation of mitotic However, PML levels were generally observed to be stable or modestly reduced at concentrations ranging from 0.015 to 0.25 µM ( Figure 1G and H). Notably, ATO-induced degradation was observed to be less effective in HaCaT compared to NB4 cells. This could be due to a less active RNF4-dependent degradation pathway or a lower basal oxidation level in the keratinocyte compared to the APL cell line.
The low concentration of ATO, sufficient to induce increased CyPN accumulation suggested that this activity is not caused by increased levels of ROS, toxic derivatives of oxygen that are known to increase in arsenic treated cells (especially at higher doses) 31 .
In did not lead to a detectable decrease in ATO-induced CyPN formation (Supplemental Figure   S3 ).
ATO blocks CyPN disintegration and PML body regeneration following cell division
To better understand the mechanism by which ATO stabilizes CyPNs in the cytoplasm, we analyzed the behavior of PML bodies in the presence and absence of this agent in living cells. To achieve this, we stably transduced HaCaT cells with a lentivirus-based vector expressing an EYFP-tagged version of PML1, one of the largest and most abundantly expressed of the PML isoforms 32 . Notably, the lentivirus-based plasmid construct used expressed EYFP-PML1 from a weak cytomegalovirus gD promoter to achieve close to endogenous expression levels 24 . In addition, we also introduced a second lentivirus vector into these cells, which expressed mCherry-Histone H2B, to visualize chromatin. Confocal microscopy time series of living cells were then generated by image acquisitions at 2 minutes intervals for up to 20 hours, a time scale which allowed for analysis of multiple cells as they traversed through mitosis.
In untreated control cells ( 
ATO-induced PML SUMOylation is counteracted by cell division
The experiments described above suggest that mitosis facilitates ATO-stimulated CyPN formation. To verify this, we assessed the ability of this drug to stimulate cytoplasmic PML accumulation in HaCaT cells treated with thymidine (TMD), a nucleoside analogue that blocks cell cycle progression in G1/S-phase. We found that the number of CyPNs per cell was strongly reduced upon treatment for 12 hours with 1 mM TMD prior to addition of 1.0 µM ATO and continued incubation for 5 or 24 hours ( Figure 3A Interestingly, the presence of TMD appeared to cause a more effective PML depletion in some of our experiments (see for example NB4 cells in Figure 3F ) suggesting that a block in cell cycle progression leads to more effective PML degradation, possibly due to prolonged exposure of PML and PML bodies to the nuclear environment under these conditions.
To more precisely delineate the fate of SUMO/Ub-modified PML in ATO-treated cycling or non-cycling cells, we employed a HaCaT-derived cell line that stably expressed FLAG-PML1 from a lentivirus-based vector. Although the FLAG-PML1 protein failed to become significantly degraded in response to ATO in these experiments (possibly due to distortion of normal PML functions due to overexpression or the presence of an N-terminal tag), we observed efficient modification of this protein by SUMO/Ub conjugation ( Figure 3H-I ).
Interestingly, a robust increase of high molecular weight FLAG-PML1 species was readily observed at 1 and 4 hours of ATO treatment, but at 24 hours we mainly detected nonconjugated PML species ( Figure 3H ). In contrast to untreated cells, the unmodified FLAG-PML1 species detected at 24 hours of ATO treatment were not extracted by a Triton X-100-based procedure, demonstrating biochemical alterations of PML into more insoluble and Figure 3H) . Furthermore, the transformation of SUMO/Ub-conjugated FLAG-PML1 into non-conjugated species was prevented in cells treated with TMD, suggesting that the reduction in SUMO-PML conjugates is promoted by cell cycle progression ( Figure 3I ).
Lastly, we analyzed the sub-cellular localization of SUMO1 and PML in untreated and ATO-treated HaCaT cells by IF. This experiment revealed an increase in SUMO-positive PML bodies in the nucleus upon treatment with ATO ( Figure 3J ). However, CyPNs consistently stained negative for SUMO1 both before and after ATO treatment ( Figure 3J ). Similar results were also obtained by using an antibody that reacts with SUMO2 and SUMO3 (data not shown). In addition, inspections of mitotic cells revealed a considerably lower level of SUMO1
within MAPS compared to the nuclear PML bodies in interphase cells. These results strongly support the notion that ATO-stimulated SUMOylation of PML primarily occurs in the nucleus.
Furthermore, in the absence of effective RNF4-dependent degradation, these conjugates may be removed upon progression through mitosis leading to sequestration of non-SUMOylated PML within CyPNs in the cytoplasm.
ATO-induced CyPN formation does not require SUMOylation and is prevented by PML mutations identified in therapy-resistant APL patients
The PML protein is organized into a tripartite (TRIM) domain at its N-terminus, which comprises the three zinc binding domains RING, B-box 1 (BB1) and B-box 2 (BB2) in addition to a coiled coil (CC) 33 . Furthermore, this protein harbors a SUMO interaction motif (SIM) at its central region and three different lysine residues (K65, K160 and K490) that can be modified by SUMOylation (Figure 4A ) 34 . To determine the requirement for SUMOylation and the different PML sub-structures in ATO-induced CyPN accumulation, we employed a previously described depletion-reconstitution approach 24 . For these experiments PML bodies were first depleted from HaCaT cells using stable expression of shRNAs against PML, and PML expression and PML bodies were subsequently regenerated by a second lentivirus-based vector expressing shRNA-resistant EYFP-PML1. Importantly, these constructs have been designed to produce close to endogenous levels of PML from a weak promoter 24 .
For 
Discussion
Previous studies have shown that ATO interacts directly with cysteine-rich motifs within the PML protein to promote its SUMOylation and subsequent ubiquitination and proteasomal degradation [6] [7] [8] [9] . Since this molecular pathway also affects the APL-associated PML/RARA oncoprotein, it is likely to play an important role in ATO-mediated clinical remission of this disease. The data presented in this study reveals an additional mechanism that does not involve SUMOylation and, instead of activating degradation, leads to redistribution of PML and PML/RARA from the nucleus to the cytoplasm (Figure 6 ). Several observations suggest that also this pathway may be implicated in the cure of APL. Firstly, the PML/RARA oncoprotein is thought to promote malignant transformation and tumor progression predominantly through its activity as a transcription repressor 12 . Since this function requires direct contact between the protein and the genome, it is expected to be lost upon sequestration of PML/RARA in the cytoplasm. Secondly, accumulation of CyPNs is observed predominantly at relatively low ATO concentrations and the activity peaks between 0.1 -1.0 µM, the same range of concentrations that is normally detected in the plasma of APL patients receiving ATO-based therapy [26] [27] [28] . Thirdly, the ability of PML to support CyPN formation is strictly dependent on cysteine residues within the BB2 motif of the PML protein, the same amino acids that recently have been shown to be important for ATO-PML interactions as well as the ATO-mediated cure of APL in mouse While PML bodies within the nucleus represent the most extensively studied compartment formed by PML, little is known about the function of MAPPs and CyPNs that are produced in mitotic and newly formed G1 cells respectively. Besides the ability of these cytoplasmic compartments to sequester PML and nucleoporins, it has also been shown that they migrate within the cytoplasm of the cell in a microtubule-dependent manner 21 .
Interestingly, PML has been shown to functionally interact with other microtubule-binding cytoplasmic organelles such as endosomes, mitochondria and endoplasmatic reticulum to regulate growth signaling and calcium homeostasis, respectively [39] [40] [41] . It will be important to identify the cytoplasmic functions of CyPNs and a potential PML-mediated gain or inhibition of these functions in ATO-treated cells. Notably, low concentrations of arsenic (0.1 µM to 0.5
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From µM), which in this study was shown to cause a significant increase in CyPN accumulation, have previously been shown to affect cell differentiation as well as calcium homeostasis [42] [43] [44] . In summary, we have identified and characterized a highly sensitive and specific response of PML, PML/RARA and PML bodies to arsenic. In addition to providing important insight into ATO-mediated cure of APL, these findings may also contribute to the development of ATObased treatment regiments that can be employed for cancers other than APL. Finally, since PML is a tumor suppressor, our study may contribute to increased understanding of tumorigenesis related to long term exposure to arsenic through drinking water 
